Heart Failure with Preserved Ejection Fraction (HFpEF): Emerging Pharmacotherapies

Doctor holding an illuminated iPad displaying a heart and heartbeat
Thought Leadership  |  01 April 2019  |  By John M. Farah, PhD


With a rising prevalence and high rates of morbidity and mortality, heart failure has become a prominent personal and public health burden. Recently, Veradigm® published a whitepaper that described heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure, and characterized ambulatory patients with HFrEF using de identified real-world data from an EHR platform Practice Fusion, a Veradigm offering. That paper briefly touched on another type of heart failure, heart failure with preserved ejection fraction (HFpEF), also referred to as diastolic heart failure. Despite similarities in clinical expression, HFrEF and HFpEF differ in their etiologies, cardiac remodeling patterns, biomarker profiles, and responsiveness to pharmacotherapy. This paper addresses HFpEF, with a focus on major comorbidities and on two classes of emerging pharmacotherapies. A retrospective data review using de-identified patient data from the EHR Practice Fusion demonstrates how real world evidence may be leveraged to offer insights regarding HFpEF.

Read HFpEF Whitepaper

Spread the word

pharmacotherapies   hfpef   healthy ejection fraction   ejection fraction   real world evidence   real world data   RWE  

Related insights